Taigen Biopharmaceuticals Ltd.
TaiGen Biopharmaceuticals pursues high‑growth infectious‑disease treatments: phase II Taigexyn (quinolone antibiotic) for pneumonia/diabetic foot, phase III TG‑1000 for influenza, plus HCV drug Furaprevir and stem‑cell mobilizer Burixafor.
Headquarters: Taiwan (TWN)
- Website: Visit Site 🔗
- Type: Corporation
Company Profile
- Sector: Hospitals and Health Care
- Industry: Medical Practices
- HQ: Taipei
Unlock the full potential.
Upgrade
Get access to Relative P/E Ratio Valuation Histogram.